|By PR Newswire||
|August 11, 2014 09:21 AM EDT||
LONDON and WILMINGTON, N.C., Aug. 11, 2014 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO) has earned a Gold Membership in CDISC, the Clinical Data Interchange Standards Consortium.
CDISC is a global non-profit organization that has established standards to support the acquisition, exchange, submission, and archive of clinical research data. CDISC is comprised of nearly 200 global organizations including leading Biotech and Pharmaceutical companies, CROs, and academic institutions. Their mission is to develop and support global data standards that enable information exchange to improve medical research with a vision toward patient care and safety.
Prior to joining, Chiltern has been following CDISC standards with experience in reporting over 100 studies using the SDTM (Study Data Tabulation Model) and ADaM (Analysis Data Model) models. Now as a member of CDISC, Chiltern will collaborate with global leaders and contribute toward the development and release of new standards. "Membership in CDISC will further enhance our capabilities in delivering quality data and outputs. It signals a commitment by Chiltern to stay out in front of the needs of our clients," explained Michael Wisniewski, Chiltern's Senior Executive Director of Biometrics.
Matthew Juler, Chiltern's Manager of Statistical Programming, Europe added: "Chiltern has been producing CDISC compliant data for a number of years, and by attaining Gold membership we look forward to becoming actively involved in the evolution of the CDISC standards. Our membership will ensure that we are able to implement the latest standards as they come online and continue to provide a high quality product for our sponsors."
Established in 1982, Chiltern is a leading global clinical CRO offering specialized services in oncology and a range of other therapeutic areas, together with global sourcing and FSP solutions. Chiltern's 2,100 people work in more than 40 countries and offer expertise, engagement and tailored responsive solutions to meet the demands of biotech and pharmaceutical partners of all sizes.
Further information is available at: www.chiltern.com.
For more information contact:
Sr. Director, Global Commercial Affairs
Chiltern International Inc.
2528 Independence Blvd. Suite 101
Wilmington, NC 28412
Tel: +1 (910) 338 4760
Email: [email protected]
Oct. 26, 2016 05:30 AM EDT Reads: 1,033
Oct. 26, 2016 05:30 AM EDT Reads: 1,011
Oct. 26, 2016 05:00 AM EDT Reads: 989
Oct. 26, 2016 05:00 AM EDT Reads: 2,567
Oct. 26, 2016 04:45 AM EDT Reads: 943
Oct. 26, 2016 04:30 AM EDT Reads: 1,192
Oct. 26, 2016 04:30 AM EDT Reads: 1,759
Oct. 26, 2016 04:15 AM EDT Reads: 1,163
Oct. 26, 2016 03:45 AM EDT Reads: 1,328
Oct. 26, 2016 03:45 AM EDT Reads: 1,020
Oct. 26, 2016 02:30 AM EDT Reads: 4,091
Oct. 26, 2016 02:30 AM EDT Reads: 1,470
Oct. 26, 2016 02:30 AM EDT Reads: 1,064
Oct. 26, 2016 01:45 AM EDT Reads: 2,764
Ask someone to architect an Internet of Things (IoT) solution and you are guaranteed to see a reference to the cloud. This would lead you to believe that IoT requires the cloud to exist. However, there are many IoT use cases where the cloud is not feasible or desirable. In his session at @ThingsExpo, Dave McCarthy, Director of Products at Bsquare Corporation, will discuss the strategies that exist to extend intelligence directly to IoT devices and sensors, freeing them from the constraints of ...
Oct. 26, 2016 01:15 AM EDT Reads: 3,119